TITLE:
Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism

CONDITION:
Hyperandrogenism

INTERVENTION:
leuprolide

SUMMARY:

      OBJECTIVES:

      I. Evaluate the beneficial effects of leuprolide depot, oral contraceptive therapy, and
      leuprolide/oral contraceptive therapy in the management of patients with ovarian
      hyperandrogenism.
    

DETAILED DESCRIPTION:

      PROTOCOL OUTLINE: This is a randomized study. Patients are randomly assigned to a 6-month
      course of leuprolide versus ethinyl estradiol/norethindrone (Ovcon 35) versus leuprolide
      plus Ovcon 35. Leuprolide is administered intramuscularly in depot form every 28 days.
    

ELIGIBILITY:
Gender: Female
Age: 15 Years to 40 Years
Criteria:

        PROTOCOL ENTRY CRITERIA:

        Disease Characteristics

          -  Ovarian hyperandrogenism with Lorenzo hirsutism score 7 to 20, with or without severe
             acne

          -  Serum hormone levels: Follicle-stimulating hormone no greater than 40 mIU/mL
             Luteinizing hormone no greater than 40 mIU/mL Testosterone 60 to 200 ng/dL
             Dehydroepiandrosterone sulfate no greater than 430 micrograms/dL
             17-hydroxyprogesterone no greater than 3.3 ng/mL in follicular phase Prolactin no
             greater than 18 ng/dL

          -  No adrenal or ovarian tumors

        Prior/Concurrent Therapy

          -  At least 6 months since exogenous steroids At least 48 hours since drugs other than
             acetaminophen, ibuprofen, and aspirin

        Patient Characteristics

          -  No malignancy, including the following carcinomas: Breast Cervix Ovary Uterus No
             other serious illness No cigarette smokers No nursing women No pregnancy within 6
             months prior to entry
      
